FILTER

Refine your search with the following facets to narrow down your results.

6 Current news of Cardiome Pharma

Merck & Co., Inc. and Cardiome Sign License Agreement for Vernakalant

14-Apr-2009 - Merck & Co., Inc. and Cardiome Pharma Corp. announced a collaboration and license agreement for the development and commercialization of vernakalant, an investigational candidate for the treatment of atrial fibrillation. The agreement provides Merck with exclusive global rights to the oral ...

Astellas Pharma atrial fibrillation clinical trials +6

Cardiome And Astellas Announce Receipt Of FDA Approvable Letter For KYNAPID(TM)

13-Aug-2008 - Cardiome Pharma Corp. and its co-development partner Astellas Pharma US, Inc. ("Astellas") today announced that they have received an action letter dated August 8, 2008 from the U.S. Food and Drug Administration (FDA) for KYNAPID(TM) (vernakalant hydrochloride) Injection for the treatment of ...

Astellas Pharma atrial fibrillation clinical trials +1

Cardiome Announces Positive Interim Phase 2b Results for Oral Vernakalant

19-Mar-2008 - Cardiome Pharma Corp. announced positive interim clinical results from its 90-day Phase 2b study of vernakalant (oral). The interim analysis demonstrated statistically significant efficacy for the patient group receiving 500mg b.i.d. of vernakalant (oral) as compared to placebo. The safety data ...

atrial fibrillation cervical cancer dosing

Cardiome Acquires Artesian Therapeutics

26-Oct-2005 - Cardiome Pharma Corp. announced that it has completed the acquisition of Artesian Therapeutics, Inc., further to the letter of intent ("LOI") announced on August 29, 2005. Artesian was founded in March of 2002 to discover and develop bi-functional small-molecule drugs for the treatment of ...

calcium cardiovascular diseases heart failures +1

Cardiome Announces Letter Of Intent To Acquire Artesian Therapeutics

31-Aug-2005 - Cardiome Pharma Corp. announced that it has executed a letter of intent ("LOI") to acquire Artesian Therapeutics, Inc., a privately held U.S. biopharmaceutical company. Headquartered in Gaithersburg, Maryland, Artesian was founded in March of 2002 to discover and develop bi-functional ...

calcium cardiovascular diseases documentation +3

Cardiome Reports Additional ACT 1 Clinical Results

08-Feb-2005 - Cardiome Pharma Corp and its co-development partner Fujisawa Healthcare, Inc. announced additional results from their recently completed 416-patient atrial arrhythmia ("AF") clinical study, called ACT 1. Top-line results for ACT 1 were announced on December 20, 2004, showing that the drug ...

atrial fibrillation dosing